What compounds target ALK?

BiohacksAI has identified 48 compounds that interact with ALK (ALK receptor tyrosine kinase). Top compounds include: erlotinib, Crizotinib, osimertinib, seliciclib, alvocidib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is ALK (ALK receptor tyrosine)?

ALK is ALK receptor tyrosine kinase. It is a molecular target for 48 compounds documented in PubMed bioassay data. UniProt ID: Q9UM73. NCBI Gene ID: 238.

ALK

MOLECULAR TARGET

ALK receptor tyrosine kinase

UniProt: Q9UM73 NCBI Gene: 23848 compounds

ALK (ALK receptor tyrosine kinase) is targeted by 48 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ALK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	erlotinib	5.55	256
2	Crizotinib	5.37	213
3	osimertinib	5.03	152
4	seliciclib	4.91	135
5	alvocidib	4.52	91
6	foretinib	4.34	76
7	tozasertib	4.33	75
8	vandetanib	4.30	73
9	ruxolitinib	4.23	68
10	ceritinib	4.19	65
11	bosutinib	4.08	58
12	bi 2536	4.01	54
13	semaxanib	3.93	50
14	midostaurin	3.85	46
15	brigatinib	3.81	44
16	pazopanib	3.69	39
17	nintedanib	3.61	36
18	canertinib	3.53	33
19	pelitinib	3.50	32
20	tae 684	3.43	30
21	fedratinib	3.40	29
22	gilteritinib	3.40	29
23	linifanib	3.33	27
24	entrectinib	3.18	23
25	alectinib	3.18	23
26	rociletinib	3.18	23
27	selitrectinib	3.14	22
28	dovitinib	3.09	21
29	jnj 7706621	3.09	21
30	upadacitinib	3.09	21
31	lestaurtinib	3.04	20
32	repotrectinib	3.00	19
33	r 406	2.83	16
34	cediranib	2.83	16
35	infigratinib	2.77	15
36	pha 665752	2.71	14
37	kw 2449	2.64	13
38	bemcentinib	2.64	13
39	ast 487	2.56	12
40	lorlatinib	2.48	11
41	bms 754807	2.30	9
42	su 014813	2.20	8
43	asp 3026	2.08	7
44	whi p131	1.95	6
45	ilorasertib	1.79	5
46	norlichexanthone	1.79	5
47	Quercetin	0.69	1
48	cycloheximide	0.69	1

About ALK as a Drug Target

ALK (ALK receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 48 compounds with documented ALK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ALK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.